Literature DB >> 20843515

Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS).

Ingar Holme1, Are H Aastveit, Niklas Hammar, Ingmar Jungner, Göran Walldius.   

Abstract

BACKGROUND AND AIMS: In contrast to lipoprotein components, few studies have analysed the importance of a combination of commonly available inflammatory markers as predictors of major cardiovascular events (MACE) in large healthy populations. We examined summary scores of inflammation and compared their predictive strength with that of lipoproteins in the Apolipoprotein MOrtality RISk (AMORIS) Study. METHOD AND
RESULTS: Using data from AMORIS and the Swedish hospital discharge and mortality registers, a prospective cohort study of 65,050 subjects with mean follow-up time of 11.8 years, we studied the association between lipoproteins, inflammatory markers and risk of acute myocardial infarction (AMI), stroke and heart failure. An inflammatory score was measured as the number of inflammatory variables (white blood cell count, haptoglobin and in a subgroup CRP) in their upper quartile or as a continuous summary score. All analyses were conducted with multivariate Cox proportional hazards analysis. The inflammatory scores added predictive information over and above classical lipids such as total cholesterol and triglycerides. Compared to the apolipoprotein B (apoB)/apolipoprotein A-1 (apoA-1) ratio, a stronger marker of CVD risk than conventional lipids, the inflammatory score added some discrimination value measured by net reclassification improvement, but added more within higher risk strata. No statistically significant biological interaction was found between lipoproteins and inflammatory markers.
CONCLUSION: The inflammation score and lipoproteins, including apoB and apoA-I, carry important and at least additive predictive information for risk of MACE. Routinely used markers of inflammation could be used in daily medical practice to assess cardiovascular risk.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843515     DOI: 10.1016/j.atherosclerosis.2010.08.049

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  25 in total

1.  Total and differential white blood cell counts in late life predict 8-year incident stroke: the Honolulu Heart Program.

Authors:  Ji Young Huh; George Webster Ross; Randi Chen; Robert D Abbott; Christina Bell; Bradley Willcox; Lenore Launer; Helen Petrovitch; Brock Kaya; Kamal Masaki
Journal:  J Am Geriatr Soc       Date:  2015-03-04       Impact factor: 5.562

2.  Gamma-glutamyl transferase and C-reactive protein as alternative markers of metabolic abnormalities and their associated comorbidites: a prospective cohort study.

Authors:  Jennifer C Melvin; Crystal Rodrigues; Lars Holmberg; Hans Garmo; Niklas Hammar; Ingmar Jungner; Göran Walldius; Mats Lambe; Wayel Jassem; Mieke Van Hemelrijck
Journal:  Int J Mol Epidemiol Genet       Date:  2012-11-15

3.  Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study.

Authors:  Mieke Van Hemelrijck; Lars Holmberg; Hans Garmo; Niklas Hammar; Göran Walldius; Elisa Binda; Mats Lambe; Ingmar Jungner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-02-04       Impact factor: 4.254

4.  Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers.

Authors:  Elaine Chiquette; Peter P Toth; Gilbert Ramirez; Michael Cobble; Robert Chilton
Journal:  Vasc Health Risk Manag       Date:  2012-11-12

5.  Information encoded in a network of inflammation proteins predicts clinical outcome after myocardial infarction.

Authors:  Francisco J Azuaje; Sophie Rodius; Lu Zhang; Yvan Devaux; Daniel R Wagner
Journal:  BMC Med Genomics       Date:  2011-07-14       Impact factor: 3.063

6.  A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels.

Authors:  Philippe Froguel; Ndeye Coumba Ndiaye; Amélie Bonnefond; Nabila Bouatia-Naji; Aurélie Dechaume; Gérard Siest; Bernard Herbeth; Mario Falchi; Leonardo Bottolo; Rosa-Maria Guéant-Rodriguez; Cécile Lecoeur; Michel R Langlois; Yann Labrune; Aimo Ruokonen; Said El Shamieh; Maria G Stathopoulou; Anita Morandi; Claudio Maffeis; David Meyre; Joris R Delanghe; Peter Jacobson; Lars Sjöström; Lena M S Carlsson; Andrew Walley; Paul Elliott; Marjo-Riita Jarvelin; George V Dedoussis; Sophie Visvikis-Siest
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

7.  Biomarker discovery in serum from patients with carotid atherosclerosis.

Authors:  Thomas J Degraba; Gerard T Hoehn; Paul A Nyquist; Honghui Wang; Ray Kenney; Denise A Gonzales; Steven J Kern; Sai-Xia Ying; Peter J Munson; Anthony F Suffredini
Journal:  Cerebrovasc Dis Extra       Date:  2011-12-03

8.  ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity.

Authors:  Min Lu; Qun Lu; Yong Zhang; Gang Tian
Journal:  J Biomed Res       Date:  2011-07

9.  Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study.

Authors:  Wahyu Wulaningsih; Karl Michaelsson; Hans Garmo; Niklas Hammar; Ingmar Jungner; Göran Walldius; Mats Lambe; Lars Holmberg; Mieke Van Hemelrijck
Journal:  BMC Public Health       Date:  2013-07-17       Impact factor: 3.295

10.  Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis.

Authors:  Wahyu Wulaningsih; Mariam Vahdaninia; Mark Rowley; Lars Holmberg; Hans Garmo; Håkan Malmstrom; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Anthonius C Coolen; Mieke Van Hemelrijck
Journal:  BMC Cancer       Date:  2015-11-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.